Latest treatment of lung cancer Stories
- Data support VAL-083's importance as a potential therapy for non-small cell lung cancer (NSCLC), including drug-resistant NSCLC - VANCOUVER, British Columbia and MENLO PARK, Calif.,
Women Conducting Groundbreaking Lung Cancer Research WASHINGTON, March 10, 2015 /PRNewswire-USNewswire/ -- During Women's History Month 2015, LUNGevity Foundation, the nation's leading lung
Data Supportive of GEN-2, an RNAi Carrier for Therapeutic Treatment of Lung Cancer LAWRENCEVILLE, N.J., Oct.
VANCOUVER, British Columbia and MENLO PARK, Calif., July 9, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB:
ORCA(TM) program includes seven Phase 2 trials in tumor types where patient need is acute, including bladder, lung, pancreas and prostate cancers BOTHELL, Wash.
A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195).
Ceritinib (brand name Zykadia(TM)) will be used for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or
Company Will Present its Targeted and Personalized Medicine Approach to Lung Cancer Somerville, MA (PRWEB) February 18, 2014 Andarix Pharmaceuticals,
A University of Colorado Cancer Center study published today in the International Journal of Radiation Oncology Biology and Physics shows that patients taking crizotinib for ALK+ non-small cell lung cancer may safely and durably use up to three courses of targeted radiation therapy to eradicate pockets of drug-resistant disease.
U.S. Preventive Services Task Force Recommends Screening for those at High Risk of Lung Cancer ST. LOUIS, Jan.
- A person or thing gazed at with wonder or curiosity, especially of a scornful kind.